Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
SAN FRANCISCO, March 2, 2021 /PRNewswire/ — Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to…
Comments Off on Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie